• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Insmed Incorporated filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    4/24/25 7:00:41 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INSM alert in real time by email
    false000110450600011045062025-04-242025-04-24

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of
    The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): April 24, 2025

    INSMED INCORPORATED
    (Exact name of registrant as specified in its charter)

    Virginia
    000-30739
    54-1972729
    (State or other jurisdiction of incorporation)
    (Commission File Number)
    (IRS Employer Identification No.)

    700 US Highway 202/206
    Bridgewater, New Jersey
     
    08807
    (Zip Code)
    (Address of principal executive offices)
       

    Registrant’s telephone number, including area code: (908) 977-9900

    Not Applicable
    (Former name or former address, if changed since last report.)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Stock, par value $0.01 per share
    INSM
    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 8.01 - Other Events

    On April 24, 2025, Insmed Incorporated (the “Company”) issued a press release, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference, announcing that it has called all $569.5 million aggregate principal amount of its remaining outstanding 0.75% Convertible Senior Notes due 2028 (the “Notes”) for redemption. The redemption will be effected pursuant to the terms of the Indenture, dated as of January 26, 2018, as supplemented by the Second Supplemental Indenture, dated as of May 13, 2021 (as so supplemented, the “Indenture”), between the Company and Computershare Trust Company, N.A., as successor trustee to Wells Fargo Bank, National Association. All then outstanding Notes will be redeemed on June 6, 2025 (the “Redemption Date”) at a redemption price equal to 100% of the principal amount of such Notes, plus accrued and unpaid interest on such Notes to, but excluding, the Redemption Date (the “Redemption Price”).

    The Notes may be surrendered for conversion at any time before 5:00 p.m., New York City time, on June 4, 2025 (or, if the Company fails to pay the Redemption Price on the Redemption Date, at any time until 5:00 p.m., New York City time, the date on which the Redemption Price is paid). The Company has elected to settle all such conversions of Notes in shares of common stock in accordance with the Indenture.

    This Current Report on Form 8-K is not a notice of redemption or convertibility of the Notes. The redemption is being made solely pursuant to the Notice of Redemption, dated April 24, 2025, relating to the Notes.

    Item 9.01
    Financial Statements and Exhibits.

    (d)
    Exhibits.

    Exhibit
    No.
     
    Description
       
    99.1
     
    Press Release issued by Insmed Incorporated, dated April 24, 2025.
    104
     
    Cover Page Interactive Data File (embedded within the Inline XBRL document).


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Dated: April 24, 2025
    INSMED INCORPORATED
       
     
    By:
    /s/ Michael A. Smith
     
    Name:
    Michael A. Smith
     
    Title:
    Chief Legal Officer and Corporate Secretary



    Get the next $INSM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INSM

    DatePrice TargetRatingAnalyst
    5/13/2025$105.00Buy
    Jefferies
    2/25/2025$100.00Outperform
    RBC Capital Mkts
    4/23/2024$48.00Buy
    Truist
    2/15/2024$42.00Outperform
    Wolfe Research
    12/8/2023$55.00Overweight
    Wells Fargo
    11/20/2023$36.00Overweight
    JP Morgan
    7/26/2023$50.00Buy
    Guggenheim
    12/9/2022$28.00Buy
    Mizuho
    More analyst ratings

    $INSM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update

      —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $92.8 Million for the First Quarter of 2025, Reflecting 23% Growth Over the First Quarter of 2024— —NDA for Brensocatib in Patients with Bronchiectasis Remains on Track, with a PDUFA Target Action Date of August 12, 2025— —Phase 2b Study of TPIP in Patients with PAH Completed; Topline Data Expected in June 2025— —Enrollment Completed for Phase 2b BiRCh Study of Brensocatib in Patients with CRSsNP; Topline Data Anticipated By the End of 2025— —MAA Filings for Brensocatib in Patients with Bronchiectasis Accepted by EMA and MHRA— —Company Reiterates 2025 Global ARIKAYCE Revenue Guidance Range of $405 Million to $425 Million,

      5/8/25 7:00:00 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Insmed To Present at the BofA Securities 2025 Health Care Conference

      BRIDGEWATER, N.J., April 29, 2025 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the BofA Securities 2025 Health Care Conference in Las Vegas on Tuesday, May 13, 2025, at 2:20 p.m. PT. This event will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Webcasts will be archived for a period of 30 days following the conclusion of the live events. About Insmed Insmed Incorporated is a people-first global biopharm

      4/29/25 7:00:00 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028

      BRIDGEWATER, N.J., April 24, 2025 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it has called all $569.5 million aggregate principal amount of its remaining outstanding 0.75% Convertible Senior Notes Due 2028 (the "Notes") (CUSIP No. 457669AB5) for redemption on June 6, 2025 (the "Redemption Date"). Insmed is redeeming the Notes as permitted under Section 11.03 of the indenture governing the Notes (the "Indenture"). Redemption Process The redemption price will be payable on the Redemption Date in cash and

      4/24/25 7:00:00 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INSM
    Leadership Updates

    Live Leadership Updates

    See more

    $INSM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List

      —Insmed Leads Science Top Employers List for Fourth Year in a Row— BRIDGEWATER, N.J., Oct. 24, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it has earned the highest ranking in Science's 2024 Top Employers Survey. The annual survey polls employees in biotechnology, pharmaceutical, and related industries to determine the 20 best employers, as well as their driving characteristics. "It is a tremendous honor to have been named the No. 1 employer in Science's annual survey for the fourth consecutive year

      10/24/24 4:05:00 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Insmed Names Drayton Wise Chief Commercial Officer

      BRIDGEWATER, N.J., May 23, 2022 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Drayton Wise as Chief Commercial Officer, effective May 23, 2022. In addition to his current responsibilities leading the global ARIKAYCE® (amikacin liposome inhalation suspension) franchise and U.S. commercial activities, Mr. Wise will assume responsibility for all of Insmed's global commercial functions. Mr. Wise will also serve as a member of Insmed's Executive Committee. "We are thrilled to promote Drayton to Chief Commercial Officer at this critical inflecti

      5/23/22 8:00:00 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for ARIKAYCE KIT issued to INSMED INC

      Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-13) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 06/01/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling

      6/2/23 4:38:39 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for ARIKAYCE KIT issued to INSMED INC

      Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-12) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 02/10/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling

      2/13/23 4:39:32 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Bonstein Sara was granted 6,508 shares, increasing direct ownership by 6% to 114,867 units (SEC Form 4)

      4 - INSMED Inc (0001104506) (Issuer)

      5/19/25 5:06:31 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Adsett Roger was granted 6,508 shares, increasing direct ownership by 5% to 143,183 units (SEC Form 4)

      4 - INSMED Inc (0001104506) (Issuer)

      5/19/25 5:06:18 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief People Strategy Officer Schaeffer Orlov S Nicole was granted 5,578 shares, increasing direct ownership by 5% to 120,221 units (SEC Form 4)

      4 - INSMED Inc (0001104506) (Issuer)

      5/19/25 5:06:06 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INSM
    SEC Filings

    See more
    • SEC Form S-8 filed by Insmed Incorporated

      S-8 - INSMED Inc (0001104506) (Filer)

      5/16/25 4:56:14 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Insmed Incorporated filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - INSMED Inc (0001104506) (Filer)

      5/16/25 4:37:46 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Insmed Incorporated

      144 - INSMED Inc (0001104506) (Subject)

      5/14/25 5:49:07 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INSM
    Financials

    Live finance-specific insights

    See more

    $INSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $INSM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update

      —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $92.8 Million for the First Quarter of 2025, Reflecting 23% Growth Over the First Quarter of 2024— —NDA for Brensocatib in Patients with Bronchiectasis Remains on Track, with a PDUFA Target Action Date of August 12, 2025— —Phase 2b Study of TPIP in Patients with PAH Completed; Topline Data Expected in June 2025— —Enrollment Completed for Phase 2b BiRCh Study of Brensocatib in Patients with CRSsNP; Topline Data Anticipated By the End of 2025— —MAA Filings for Brensocatib in Patients with Bronchiectasis Accepted by EMA and MHRA— —Company Reiterates 2025 Global ARIKAYCE Revenue Guidance Range of $405 Million to $425 Million,

      5/8/25 7:00:00 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025

      BRIDGEWATER, N.J., April 23, 2025 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its first-quarter 2025 financial results on Thursday, May 8, 2025. Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, May 8, 2025, to discuss financial results and provide a business update. Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S.) and (646) 960-0278 (international) and referencing access code

      4/23/25 7:00:00 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update

      —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $104.4 Million for Fourth-Quarter and $363.7 Million for Full-Year 2024, Reflecting 19% Annual Growth and Exceeding the Upper End of Full-Year 2024 Guidance Range— —Company Reiterates 2025 Global ARIKAYCE Revenue Guidance of $405 Million to $425 Million, Reflecting Double-Digit Growth Compared to 2024— —NDA for Brensocatib in Patients with Bronchiectasis Accepted by FDA and Granted Priority Review with a PDUFA Target Action Date of August 12, 2025— —Phase 2b Study of TPIP in Patients with PAH, Phase 2b BiRCh Study of Brensocatib in Patients with CRSsNP, and Phase 3 ENCORE Study of ARIKAYCE Remain on Track for Topline Data

      2/20/25 7:00:00 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Insmed Incorporated

      SC 13G/A - INSMED Inc (0001104506) (Subject)

      11/14/24 1:22:37 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Insmed Incorporated

      SC 13G - INSMED Inc (0001104506) (Subject)

      9/3/24 5:22:55 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Insmed Incorporated (Amendment)

      SC 13G/A - INSMED Inc (0001104506) (Subject)

      2/16/24 5:43:57 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Insmed with a new price target

      Jefferies initiated coverage of Insmed with a rating of Buy and set a new price target of $105.00

      5/13/25 9:43:52 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Insmed with a new price target

      RBC Capital Mkts initiated coverage of Insmed with a rating of Outperform and set a new price target of $100.00

      2/25/25 7:09:15 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Truist initiated coverage on Insmed with a new price target

      Truist initiated coverage of Insmed with a rating of Buy and set a new price target of $48.00

      4/23/24 6:29:24 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care